Two randomized, controlled trials evaluated the efficacy and safety of obicetrapib, an oral cholesteryl ester transfer protein (CETP) inhibitor, in lowering low-density lipoprotein (LDL) cholesterol in patients at high risk for atherosclerotic cardiovascular disease (ASCVD).
Both trials show that obicetrapib is effective in reducing LDL cholesterol, with enhanced efficacy when combined with ezetimibe. The FDC offers a potent oral treatment option for high-risk patients who need additional LDL-C lowering beyond standard therapy. These findings suggest that obicetrapib may be a useful adjunct to lipid lowering in high risk patients, and a cardiovascular outcomes trial is underway. Source: https://www.nejm.org/; https://www.thelancet.com/
A global study suggested that most patients with coronary heart disease (CHD) have Lipoprotein (a)…
A recent article explored the science and skepticism surrounding seed oils. These oils—extracted from sources…
A Canadian study of adults with high blood pressure (BP) found no difference in health…
A UK longitudinal associations study revealed that hyperlipidemias and inflammation independently and together raise the…
A study shows that eating a lot of highly processed foods is likely causing a…
Two recent studies highlight the importance of physical activity volume and intensity in reducing cardiovascular…
This website uses cookies.